NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial Of NV-387 Oral Gummies To Treat The Current Bundibugyo Ebolavirus
NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned
NanoViricides is asking regulators in the DRC to let them test a new medicine for Ebola in real patients. This shows the company is moving forward with their treatment idea, which is important to watch because it tells you if their science is actually working.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.